Page last updated: 2024-09-05

sorafenib and tivozanib

sorafenib has been researched along with tivozanib in 24 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(tivozanib)
Trials
(tivozanib)
Recent Studies (post-2010) (tivozanib)
6,5207305,25110523100

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)tivozanib (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0709
Fibroblast growth factor 2Homo sapiens (human)0.0709
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0709
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0023
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0032
Ephrin type-B receptor 2Homo sapiens (human)0.0175
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0017
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0783
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.07

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (54.17)24.3611
2020's11 (45.83)2.80

Authors

AuthorsStudies
Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY1
Chen, JH; Deng, YL; Kania, RS; McTigue, M; Murray, BW; Solowiej, J1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, Y; Fan, L; Gong, Y; Guo, S; Kang, F; Pang, X; Peng, L; Zhan, M1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Garnick, MB1
Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P1
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A1
Eisen, T; Hutson, TE; Lipatov, O; Molina, AM; Motzer, R; Nosov, D; Sternberg, CN; Tomczak, P1
Belsey, J; Eisen, T; Escudier, B; Gibson, D; Morgan, J; Motzer, R; Porta, C1
Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E1
Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Rini, BI; Verzoni, E1
Bex, A1
Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M1
Wright, KM1
Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Powers, D; Rini, BI; Verzoni, E1
Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y1
Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Rini, BI; Szarek, M1
Amiri-Kordestani, L; Beaver, JA; Bhatnagar, V; Chang, E; Chen, XH; Fiero, MH; Fourie Zirkelbach, J; Goldberg, KB; Ibrahim, A; Kluetz, PG; Pazdur, R; Qiu, J; Ricks, TK; Tang, S; Weinstock, C; Yu, J; Zahalka, E; Zhang, L; Zhao, M1
Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB1
Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Meza, L; Pal, SK; Porta, C; Rini, B; Verzoni, E1

Reviews

8 review(s) available for sorafenib and tivozanib

ArticleYear
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, Volume: 28, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A

2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Anti-cancer drugs, 2016, Volume: 27, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    European urology, 2017, Volume: 71, Issue:3

    Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2017
The role of tivozanib in advanced renal cell carcinoma therapy.
    Expert review of anticancer therapy, 2018, Volume: 18, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2018
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
    Future oncology (London, England), 2019, Volume: 15, Issue:22

    Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome

2019
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
    Cancer treatment reviews, 2020, Volume: 84

    Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib

2020
Targeted therapy for metastatic renal cell carcinoma.
    The Cochrane database of systematic reviews, 2020, 10-14, Volume: 10

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib

2020

Trials

7 trial(s) available for sorafenib and tivozanib

ArticleYear
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Status; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome

2013
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 94

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome; Young Adult

2018
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
    The Lancet. Oncology, 2020, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Quinolines; Research Design; Sorafenib; Survival Rate

2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
    European urology, 2020, Volume: 78, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Phenylurea Compounds; Quinolines; Retreatment; Sorafenib; Survival Rate

2020
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
    Clinical genitourinary cancer, 2021, Volume: 19, Issue:5

    Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Sorafenib

2021
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
    Clinical genitourinary cancer, 2022, Volume: 20, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A

2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
    The oncologist, 2023, 03-17, Volume: 28, Issue:3

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Sorafenib

2023

Other Studies

9 other study(ies) available for sorafenib and tivozanib

ArticleYear
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2

2010
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, Nov-06, Volume: 109, Issue:45

    Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Crystallography, X-Ray; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Kidney Neoplasms; Models, Molecular; Molecular Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Design, synthesis and biological evaluation of deuterated Tivozanib for improving pharmacokinetic properties.
    Bioorganic & medicinal chemistry letters, 2015, Jun-01, Volume: 25, Issue:11

    Topics: Animals; Area Under Curve; Deuterium; Enzyme Inhibitors; Half-Life; Male; Phenylurea Compounds; Quinolines; Rats; Rats, Sprague-Dawley

2015
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib

2013
Sequencing therapy for advanced renal cancer.
    The Lancet. Oncology, 2020, Volume: 21, Issue:1

    Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib

2020
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
    Oncology (Williston Park, N.Y.), 2020, Jul-15, Volume: 34, Issue:7

    Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2020
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 02-01, Volume: 28, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Drug Approval; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome

2022